{"data":[{"accessionNo":"0001753037-26-000007","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001736730","issuerName":"CAMP4 THERAPEUTICS CORPORATION","ticker":"CAMP","cusip":"13463J101","securityClass":"Common Stock","eventDate":"2026-08-27","reportingPerson":"Kush Parmar","reportingCik":"0001664281","personType":"IN","sharesOwned":6370125,"percentOfClass":9.9,"filedAt":"2026-08-31","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001753037-26-000007","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001736730","issuerName":"CAMP4 THERAPEUTICS CORPORATION","ticker":"CAMP","cusip":"13463J101","securityClass":"Common Stock","eventDate":"2026-08-27","reportingPerson":"Andrew J. Schwab","reportingCik":"0001598549","personType":"IN","sharesOwned":6379125,"percentOfClass":9.9,"filedAt":"2026-08-31","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001753037-26-000007","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001736730","issuerName":"CAMP4 THERAPEUTICS CORPORATION","ticker":"CAMP","cusip":"13463J101","securityClass":"Common Stock","eventDate":"2026-08-27","reportingPerson":"5AM Ventures VII, L.P.","reportingCik":"0001844435","personType":"PN","sharesOwned":4034085,"percentOfClass":6.3,"filedAt":"2026-08-31","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001753037-26-000007","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001736730","issuerName":"CAMP4 THERAPEUTICS CORPORATION","ticker":"CAMP","cusip":"13463J101","securityClass":"Common Stock","eventDate":"2026-08-27","reportingPerson":"5AM Partners VII, LLC","reportingCik":"0001873545","personType":"OO","sharesOwned":4034085,"percentOfClass":6.3,"filedAt":"2026-08-31","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001753037-26-000007","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001736730","issuerName":"CAMP4 THERAPEUTICS CORPORATION","ticker":"CAMP","cusip":"13463J101","securityClass":"Common Stock","eventDate":"2026-08-27","reportingPerson":"5AM Ventures VI, L.P.","reportingCik":"0001753037","personType":"PN","sharesOwned":2033270,"percentOfClass":3.2,"filedAt":"2026-08-31","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001753037-26-000007","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001736730","issuerName":"CAMP4 THERAPEUTICS CORPORATION","ticker":"CAMP","cusip":"13463J101","securityClass":"Common Stock","eventDate":"2026-08-27","reportingPerson":"5AM Partners VI, LLC","reportingCik":"0001829051","personType":"OO","sharesOwned":2033270,"percentOfClass":3.2,"filedAt":"2026-08-31","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001753037-26-000007","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001736730","issuerName":"CAMP4 THERAPEUTICS CORPORATION","ticker":"CAMP","cusip":"13463J101","securityClass":"Common Stock","eventDate":"2026-08-27","reportingPerson":"5AM Opportunities II (GP), LLC","reportingCik":"0001873515","personType":"OO","sharesOwned":302770,"percentOfClass":0.5,"filedAt":"2026-08-31","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001753037-26-000007","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001736730","issuerName":"CAMP4 THERAPEUTICS CORPORATION","ticker":"CAMP","cusip":"13463J101","securityClass":"Common Stock","eventDate":"2026-08-27","reportingPerson":"5AM Opportunities II, L.P.","reportingCik":"0001844401","personType":"PN","sharesOwned":302770,"percentOfClass":0.5,"filedAt":"2026-08-31","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001193125-26-357272","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001736730","issuerName":"Camp4 Therapeutics Corporation","ticker":"CAMP","cusip":"13463J101","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-08-13","reportingPerson":"Amir Nashat","reportingCik":"0001575843","personType":"IN","sharesOwned":3932251,"percentOfClass":6.3,"filedAt":"2026-08-19","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001193125-26-357272","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001736730","issuerName":"Camp4 Therapeutics Corporation","ticker":"CAMP","cusip":"13463J101","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-08-13","reportingPerson":"Polaris Management Co. VII, L.L.C.","reportingCik":"0001678203","personType":"OO","sharesOwned":3023161,"percentOfClass":4.8,"filedAt":"2026-08-19","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001193125-26-357272","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001736730","issuerName":"Camp4 Therapeutics Corporation","ticker":"CAMP","cusip":"13463J101","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-08-13","reportingPerson":"Polaris Partners VII, L.P.","reportingCik":"0001611189","personType":"PN","sharesOwned":2825500,"percentOfClass":4.5,"filedAt":"2026-08-19","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001193125-26-357272","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001736730","issuerName":"Camp4 Therapeutics Corporation","ticker":"CAMP","cusip":"13463J101","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-08-13","reportingPerson":"Polaris Partners GP X, L.L.C.","reportingCik":"0001910575","personType":"OO","sharesOwned":909090,"percentOfClass":1.4,"filedAt":"2026-08-19","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001193125-26-357272","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001736730","issuerName":"Camp4 Therapeutics Corporation","ticker":"CAMP","cusip":"13463J101","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-08-13","reportingPerson":"Polaris Partners X, L.P.","reportingCik":"0001910577","personType":"PN","sharesOwned":909090,"percentOfClass":1.4,"filedAt":"2026-08-19","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001193125-26-357272","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001736730","issuerName":"Camp4 Therapeutics Corporation","ticker":"CAMP","cusip":"13463J101","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-08-13","reportingPerson":"Brian Chee","reportingCik":"0001295675","personType":"IN","sharesOwned":909090,"percentOfClass":1.4,"filedAt":"2026-08-19","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001193125-26-357272","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001736730","issuerName":"Camp4 Therapeutics Corporation","ticker":"CAMP","cusip":"13463J101","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-08-13","reportingPerson":"Amy Schulman","reportingCik":"0001438226","personType":"IN","sharesOwned":909090,"percentOfClass":1.4,"filedAt":"2026-08-19","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001193125-26-357272","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001736730","issuerName":"Camp4 Therapeutics Corporation","ticker":"CAMP","cusip":"13463J101","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-08-13","reportingPerson":"Polaris Entrepreneurs' Fund VII, L.P.","reportingCik":"0001615991","personType":"PN","sharesOwned":197661,"percentOfClass":0.3,"filedAt":"2026-08-19","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001172661-26-003419","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001736730","issuerName":"Camp4 Therapeutics Corp.","ticker":"CAMP","cusip":"13463J101","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"BALYASNY ASSET MANAGEMENT L.P.","reportingCik":null,"personType":"IA,PN","sharesOwned":2591097,"percentOfClass":4.99,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001172661-26-003419","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001736730","issuerName":"Camp4 Therapeutics Corp.","ticker":"CAMP","cusip":"13463J101","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"Balyasny Asset Management Holdings LP","reportingCik":null,"personType":"HC,PN","sharesOwned":2591097,"percentOfClass":4.99,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001172661-26-003419","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001736730","issuerName":"Camp4 Therapeutics Corp.","ticker":"CAMP","cusip":"13463J101","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"Dmitry Balyasny","reportingCik":null,"personType":"HC,IN","sharesOwned":2591097,"percentOfClass":4.99,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001172661-26-003419","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001736730","issuerName":"Camp4 Therapeutics Corp.","ticker":"CAMP","cusip":"13463J101","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"Dames GP LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":2591097,"percentOfClass":4.99,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001172661-26-003419","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001736730","issuerName":"Camp4 Therapeutics Corp.","ticker":"CAMP","cusip":"13463J101","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"BAM GP LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":2591097,"percentOfClass":4.99,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001493152-26-036926","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001736730","issuerName":"Camp4 Therapeutics Corp","ticker":"CAMP","cusip":"13463J101","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-08-03","reportingPerson":"Trails Edge Capital Partners, LP","reportingCik":null,"personType":"IA,PN","sharesOwned":3790636,"percentOfClass":6,"filedAt":"2026-08-10","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001493152-26-036926","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001736730","issuerName":"Camp4 Therapeutics Corp","ticker":"CAMP","cusip":"13463J101","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-08-03","reportingPerson":"Trails Edge Biotechnology Master Fund, LP","reportingCik":null,"personType":"PN","sharesOwned":3790636,"percentOfClass":6,"filedAt":"2026-08-10","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001493152-26-036926","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001736730","issuerName":"Camp4 Therapeutics Corp","ticker":"CAMP","cusip":"13463J101","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-08-03","reportingPerson":"Ortav Yehudai","reportingCik":null,"personType":"IN","sharesOwned":3790636,"percentOfClass":6,"filedAt":"2026-08-10","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001753037-26-000003","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001736730","issuerName":"CAMP4 THERAPEUTICS CORPORATION","ticker":"CAMP","cusip":"13463J101","securityClass":"Common Stock","eventDate":"2026-08-03","reportingPerson":"Andrew J. Schwab","reportingCik":"0001598549","personType":"IN","sharesOwned":6313434,"percentOfClass":9.9,"filedAt":"2026-08-05","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001753037-26-000003","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001736730","issuerName":"CAMP4 THERAPEUTICS CORPORATION","ticker":"CAMP","cusip":"13463J101","securityClass":"Common Stock","eventDate":"2026-08-03","reportingPerson":"Kush Parmar","reportingCik":"0001664281","personType":"IN","sharesOwned":6304434,"percentOfClass":9.9,"filedAt":"2026-08-05","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001753037-26-000003","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001736730","issuerName":"CAMP4 THERAPEUTICS CORPORATION","ticker":"CAMP","cusip":"13463J101","securityClass":"Common Stock","eventDate":"2026-08-03","reportingPerson":"5AM Partners VII, LLC","reportingCik":"0001873545","personType":"OO","sharesOwned":3376519,"percentOfClass":5.3,"filedAt":"2026-08-05","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001753037-26-000003","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001736730","issuerName":"CAMP4 THERAPEUTICS CORPORATION","ticker":"CAMP","cusip":"13463J101","securityClass":"Common Stock","eventDate":"2026-08-03","reportingPerson":"5AM Ventures VII, L.P.","reportingCik":"0001844435","personType":"PN","sharesOwned":3376519,"percentOfClass":5.3,"filedAt":"2026-08-05","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001753037-26-000003","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001736730","issuerName":"CAMP4 THERAPEUTICS CORPORATION","ticker":"CAMP","cusip":"13463J101","securityClass":"Common Stock","eventDate":"2026-08-03","reportingPerson":"5AM Ventures VI, L.P.","reportingCik":"0001753037","personType":"PN","sharesOwned":2625145,"percentOfClass":4.2,"filedAt":"2026-08-05","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001753037-26-000003","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001736730","issuerName":"CAMP4 THERAPEUTICS CORPORATION","ticker":"CAMP","cusip":"13463J101","securityClass":"Common Stock","eventDate":"2026-08-03","reportingPerson":"5AM Partners VI, LLC","reportingCik":"0001829051","personType":"OO","sharesOwned":2625145,"percentOfClass":4.2,"filedAt":"2026-08-05","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001753037-26-000003","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001736730","issuerName":"CAMP4 THERAPEUTICS CORPORATION","ticker":"CAMP","cusip":"13463J101","securityClass":"Common Stock","eventDate":"2026-08-03","reportingPerson":"5AM Opportunities II (GP), LLC","reportingCik":"0001873515","personType":"OO","sharesOwned":302770,"percentOfClass":0.5,"filedAt":"2026-08-05","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001753037-26-000003","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001736730","issuerName":"CAMP4 THERAPEUTICS CORPORATION","ticker":"CAMP","cusip":"13463J101","securityClass":"Common Stock","eventDate":"2026-08-03","reportingPerson":"5AM Opportunities II, L.P.","reportingCik":"0001844401","personType":"PN","sharesOwned":302770,"percentOfClass":0.5,"filedAt":"2026-08-05","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001193125-26-225173","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001736730","issuerName":"Camp4 Therapeutics Corp.","ticker":"CAMP","cusip":"13463J101","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Dmitry Balyasny","reportingCik":null,"personType":"HC,IN","sharesOwned":2632437,"percentOfClass":5.07,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001193125-26-225173","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001736730","issuerName":"Camp4 Therapeutics Corp.","ticker":"CAMP","cusip":"13463J101","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Dames GP LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":2632437,"percentOfClass":5.07,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001193125-26-225173","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001736730","issuerName":"Camp4 Therapeutics Corp.","ticker":"CAMP","cusip":"13463J101","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Balyasny Asset Management Holdings LP","reportingCik":null,"personType":"HC,PN","sharesOwned":2632437,"percentOfClass":5.07,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001193125-26-225173","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001736730","issuerName":"Camp4 Therapeutics Corp.","ticker":"CAMP","cusip":"13463J101","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"BAM GP LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":2632437,"percentOfClass":5.07,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001193125-26-225173","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001736730","issuerName":"Camp4 Therapeutics Corp.","ticker":"CAMP","cusip":"13463J101","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Balyasny Asset Management L.P.","reportingCik":null,"personType":"IA,PN","sharesOwned":2632437,"percentOfClass":5.07,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001953107-26-000005","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001736730","issuerName":"CAMP4 THERAPEUTICS CORPORATION","ticker":"CAMP","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-03-09","reportingPerson":"Everest Aggregator, LP","reportingCik":"0002040426","personType":"PN","sharesOwned":2495562,"percentOfClass":4.8,"filedAt":"2026-03-11","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001953107-26-000005","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001736730","issuerName":"CAMP4 THERAPEUTICS CORPORATION","ticker":"CAMP","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-03-09","reportingPerson":"Enavate Sciences GP, LLC","reportingCik":"0001953107","personType":"OO","sharesOwned":2495562,"percentOfClass":4.8,"filedAt":"2026-03-11","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001213900-26-016645","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001736730","issuerName":"Camp4 Therapeutics Corp","ticker":"CAMP","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Vivo Opportunity Fund Holdings, L.P.","reportingCik":null,"personType":"PN","sharesOwned":3856991,"percentOfClass":7.4,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001213900-26-016645","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001736730","issuerName":"Camp4 Therapeutics Corp","ticker":"CAMP","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Vivo Opportunity, LLC","reportingCik":null,"personType":"OO","sharesOwned":3856991,"percentOfClass":7.4,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001213900-26-016645","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001736730","issuerName":"Camp4 Therapeutics Corp","ticker":"CAMP","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Vivo Opportunity Cayman Fund, L.P.","reportingCik":null,"personType":"PN","sharesOwned":389577,"percentOfClass":0.8,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001213900-26-016645","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001736730","issuerName":"Camp4 Therapeutics Corp","ticker":"CAMP","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Vivo Opportunity Cayman, LLC","reportingCik":null,"personType":"OO","sharesOwned":389577,"percentOfClass":0.8,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0000315066-26-000391","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001736730","issuerName":"CAMP4 THERAPEUTICS CORPORATION","ticker":"CAMP","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2025-12-31","reportingPerson":"FMR LLC","reportingCik":null,"personType":"HC","sharesOwned":4918243,"percentOfClass":9.5,"filedAt":"2026-02-05","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0000315066-26-000391","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001736730","issuerName":"CAMP4 THERAPEUTICS CORPORATION","ticker":"CAMP","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2025-12-31","reportingPerson":"Abigail P. Johnson","reportingCik":null,"personType":"IN","sharesOwned":4918243,"percentOfClass":9.5,"filedAt":"2026-02-05","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001274173-26-000026","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001736730","issuerName":"CAMP4 THERAPEUTICS CORP","ticker":"CAMP","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"JANUS HENDERSON GROUP PLC","reportingCik":null,"personType":"IA,HC","sharesOwned":6307636,"percentOfClass":12.2,"filedAt":"2026-01-08","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001953107-25-000021","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001736730","issuerName":"CAMP4 THERAPEUTICS CORPORATION","ticker":"CAMP","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-19","reportingPerson":"Everest Aggregator, LP","reportingCik":"0002040426","personType":"PN","sharesOwned":3127360,"percentOfClass":6,"filedAt":"2025-12-23","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001953107-25-000021","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001736730","issuerName":"CAMP4 THERAPEUTICS CORPORATION","ticker":"CAMP","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-19","reportingPerson":"Enavate Sciences GP, LLC","reportingCik":"0001953107","personType":"OO","sharesOwned":3127360,"percentOfClass":6,"filedAt":"2025-12-23","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001104659-25-120225","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001736730","issuerName":"Camp4 Therapeutics Corp","ticker":"CAMP","cusip":null,"securityClass":"Common stock, par value $0.0001 per share","eventDate":"2025-09-10","reportingPerson":"Matthew D. Perry","reportingCik":null,"personType":"HC,IN","sharesOwned":4886722,"percentOfClass":9.99,"filedAt":"2025-12-11","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001104659-25-120225","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001736730","issuerName":"Camp4 Therapeutics Corp","ticker":"CAMP","cusip":null,"securityClass":"Common stock, par value $0.0001 per share","eventDate":"2025-09-10","reportingPerson":"Coastlands Capital LP","reportingCik":null,"personType":"IA,PN","sharesOwned":4886722,"percentOfClass":9.99,"filedAt":"2025-12-11","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001104659-25-120225","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001736730","issuerName":"Camp4 Therapeutics Corp","ticker":"CAMP","cusip":null,"securityClass":"Common stock, par value $0.0001 per share","eventDate":"2025-09-10","reportingPerson":"Coastlands Capital Partners LP","reportingCik":null,"personType":"PN","sharesOwned":4886722,"percentOfClass":9.99,"filedAt":"2025-12-11","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001104659-25-120225","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001736730","issuerName":"Camp4 Therapeutics Corp","ticker":"CAMP","cusip":null,"securityClass":"Common stock, par value $0.0001 per share","eventDate":"2025-09-10","reportingPerson":"Coastlands Capital GP LLC","reportingCik":null,"personType":"OO","sharesOwned":4886722,"percentOfClass":9.99,"filedAt":"2025-12-11","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001104659-25-120225","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001736730","issuerName":"Camp4 Therapeutics Corp","ticker":"CAMP","cusip":null,"securityClass":"Common stock, par value $0.0001 per share","eventDate":"2025-09-10","reportingPerson":"Coastlands Capital LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":4886722,"percentOfClass":9.99,"filedAt":"2025-12-11","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001869128-25-000004","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001736730","issuerName":"CAMP4 THERAPEUTICS CORPORATION","ticker":"CAMP","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"Michael P. Rubin","reportingCik":null,"personType":"IN","sharesOwned":2238244,"percentOfClass":4.8,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001656629-25-000005","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001736730","issuerName":"CAMP4 THERAPEUTICS CORPORATION","ticker":"CAMP","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"Marc L. Andreessen","reportingCik":null,"personType":"IN","sharesOwned":2125339,"percentOfClass":4.5,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001656629-25-000005","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001736730","issuerName":"CAMP4 THERAPEUTICS CORPORATION","ticker":"CAMP","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"Benjamin A. Horowitz","reportingCik":null,"personType":"IN","sharesOwned":2125339,"percentOfClass":4.5,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001656629-25-000005","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001736730","issuerName":"CAMP4 THERAPEUTICS CORPORATION","ticker":"CAMP","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"AH Bio Fund I, L.P.","reportingCik":null,"personType":"PN","sharesOwned":1579885,"percentOfClass":3.4,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001656629-25-000005","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001736730","issuerName":"CAMP4 THERAPEUTICS CORPORATION","ticker":"CAMP","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"AH Equity Partners Bio I, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":1579885,"percentOfClass":3.4,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001869128-25-000004","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001736730","issuerName":"CAMP4 THERAPEUTICS CORPORATION","ticker":"CAMP","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"Northpond Ventures II, LP","reportingCik":null,"personType":"PN","sharesOwned":1003193,"percentOfClass":2.1,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001869128-25-000004","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001736730","issuerName":"CAMP4 THERAPEUTICS CORPORATION","ticker":"CAMP","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"Northpond Ventures II GP, LLC","reportingCik":null,"personType":"OO","sharesOwned":1003193,"percentOfClass":2.1,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001869128-25-000004","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001736730","issuerName":"CAMP4 THERAPEUTICS CORPORATION","ticker":"CAMP","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"Northpond Ventures III GP, LLC","reportingCik":null,"personType":"OO","sharesOwned":0,"percentOfClass":1.6,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001869128-25-000004","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001736730","issuerName":"CAMP4 THERAPEUTICS CORPORATION","ticker":"CAMP","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"Northpond Ventures III, LP","reportingCik":null,"personType":"PN","sharesOwned":763636,"percentOfClass":1.6,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001656629-25-000005","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001736730","issuerName":"CAMP4 THERAPEUTICS CORPORATION","ticker":"CAMP","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"AH Bio Fund IV, L.P.","reportingCik":null,"personType":"PN","sharesOwned":545454,"percentOfClass":1.2,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001656629-25-000005","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001736730","issuerName":"CAMP4 THERAPEUTICS CORPORATION","ticker":"CAMP","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"AH Equity Partners Bio IV, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":545454,"percentOfClass":1.2,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001869128-25-000004","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001736730","issuerName":"CAMP4 THERAPEUTICS CORPORATION","ticker":"CAMP","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"Northpond Ventures GP, LLC","reportingCik":null,"personType":"OO","sharesOwned":471415,"percentOfClass":1,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001869128-25-000004","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001736730","issuerName":"CAMP4 THERAPEUTICS CORPORATION","ticker":"CAMP","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"Northpond Ventures, LP","reportingCik":null,"personType":"PN","sharesOwned":471415,"percentOfClass":1,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0000315066-25-002916","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001736730","issuerName":"CAMP4 THERAPEUTICS CORPORATION","ticker":"CAMP","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2025-10-31","reportingPerson":"FMR LLC","reportingCik":null,"personType":"HC","sharesOwned":3145663,"percentOfClass":6.7,"filedAt":"2025-11-07","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0000315066-25-002916","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001736730","issuerName":"CAMP4 THERAPEUTICS CORPORATION","ticker":"CAMP","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2025-10-31","reportingPerson":"Abigail P. Johnson","reportingCik":null,"personType":"IN","sharesOwned":3145663,"percentOfClass":6.7,"filedAt":"2025-11-07","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0000315066-25-002314","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001736730","issuerName":"CAMP4 THERAPEUTICS CORP","ticker":"CAMP","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2025-09-30","reportingPerson":"FMR LLC","reportingCik":null,"personType":"HC","sharesOwned":3023434,"percentOfClass":15,"filedAt":"2025-10-07","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0000315066-25-002314","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001736730","issuerName":"CAMP4 THERAPEUTICS CORP","ticker":"CAMP","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2025-09-30","reportingPerson":"Abigail P. Johnson","reportingCik":null,"personType":"IN","sharesOwned":3023434,"percentOfClass":15,"filedAt":"2025-10-07","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001193125-25-226248","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001736730","issuerName":"CAMP4 Therapeutics Corporation","ticker":"CAMP","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"HVST-TOPE LLC","reportingCik":null,"personType":"OO","sharesOwned":1271948,"percentOfClass":2.7,"filedAt":"2025-10-01","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001193125-25-226248","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001736730","issuerName":"CAMP4 Therapeutics Corporation","ticker":"CAMP","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"HarbourVest Partners L.P.","reportingCik":null,"personType":"IA","sharesOwned":1271948,"percentOfClass":2.7,"filedAt":"2025-10-01","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001193125-25-226248","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001736730","issuerName":"CAMP4 Therapeutics Corporation","ticker":"CAMP","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"HarbourVest Partners, LLC","reportingCik":null,"personType":"IA","sharesOwned":1271948,"percentOfClass":2.7,"filedAt":"2025-10-01","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001193125-25-226248","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001736730","issuerName":"CAMP4 Therapeutics Corporation","ticker":"CAMP","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"SMRS-TOPE LLC","reportingCik":null,"personType":"OO","sharesOwned":1271948,"percentOfClass":2.7,"filedAt":"2025-10-01","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001213900-25-088676","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001736730","issuerName":"Camp4 Therapeutics Corp","ticker":"CAMP","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-11","reportingPerson":"Vivo Opportunity Fund Holdings, L.P.","reportingCik":null,"personType":"PN","sharesOwned":3561793,"percentOfClass":7.6,"filedAt":"2025-09-17","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001213900-25-088676","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001736730","issuerName":"Camp4 Therapeutics Corp","ticker":"CAMP","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-11","reportingPerson":"Vivo Opportunity, LLC","reportingCik":null,"personType":"OO","sharesOwned":3561793,"percentOfClass":7.6,"filedAt":"2025-09-17","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001213900-25-088676","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001736730","issuerName":"Camp4 Therapeutics Corp","ticker":"CAMP","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-11","reportingPerson":"Vivo Opportunity Cayman Fund, L.P.","reportingCik":null,"personType":"PN","sharesOwned":359775,"percentOfClass":0.8,"filedAt":"2025-09-17","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001213900-25-088676","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001736730","issuerName":"Camp4 Therapeutics Corp","ticker":"CAMP","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-11","reportingPerson":"Vivo Opportunity Cayman, LLC","reportingCik":null,"personType":"OO","sharesOwned":359775,"percentOfClass":0.8,"filedAt":"2025-09-17","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001172661-25-004132","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001736730","issuerName":"Camp4 Therapeutics Corp","ticker":"CAMP","cusip":null,"securityClass":"Common stock, par value $0.0001 per share","eventDate":"2025-09-10","reportingPerson":"Matthew D. Perry","reportingCik":null,"personType":"HC,IN","sharesOwned":4886722,"percentOfClass":10,"filedAt":"2025-09-16","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001172661-25-004132","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001736730","issuerName":"Camp4 Therapeutics Corp","ticker":"CAMP","cusip":null,"securityClass":"Common stock, par value $0.0001 per share","eventDate":"2025-09-10","reportingPerson":"Coastlands Capital LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":4886722,"percentOfClass":10,"filedAt":"2025-09-16","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001172661-25-004132","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001736730","issuerName":"Camp4 Therapeutics Corp","ticker":"CAMP","cusip":null,"securityClass":"Common stock, par value $0.0001 per share","eventDate":"2025-09-10","reportingPerson":"Coastlands Capital GP LLC","reportingCik":null,"personType":"OO","sharesOwned":4886722,"percentOfClass":10,"filedAt":"2025-09-16","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001172661-25-004132","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001736730","issuerName":"Camp4 Therapeutics Corp","ticker":"CAMP","cusip":null,"securityClass":"Common stock, par value $0.0001 per share","eventDate":"2025-09-10","reportingPerson":"Coastlands Capital Partners LP","reportingCik":null,"personType":"PN","sharesOwned":4886722,"percentOfClass":10,"filedAt":"2025-09-16","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001172661-25-004132","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001736730","issuerName":"Camp4 Therapeutics Corp","ticker":"CAMP","cusip":null,"securityClass":"Common stock, par value $0.0001 per share","eventDate":"2025-09-10","reportingPerson":"Coastlands Capital LP","reportingCik":null,"personType":"IA,PN","sharesOwned":4886722,"percentOfClass":10,"filedAt":"2025-09-16","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001953107-25-000007","formType":"SCHEDULE 13D/A","amendmentNo":1,"issuerCik":"0001736730","issuerName":"CAMP4 THERAPEUTICS CORPORATION","ticker":"CAMP","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-09-11","reportingPerson":"Everest Aggregator, LP","reportingCik":"0002040426","personType":"PN","sharesOwned":3785802,"percentOfClass":8.1,"filedAt":"2025-09-15","canonicalUrl":"https://xoomar.com/markets/stocks/camp"},{"accessionNo":"0001953107-25-000007","formType":"SCHEDULE 13D/A","amendmentNo":1,"issuerCik":"0001736730","issuerName":"CAMP4 THERAPEUTICS CORPORATION","ticker":"CAMP","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-09-11","reportingPerson":"Enavate Sciences GP, LLC","reportingCik":"0001953107","personType":"OO","sharesOwned":3785802,"percentOfClass":8.1,"filedAt":"2025-09-15","canonicalUrl":"https://xoomar.com/markets/stocks/camp"}],"updatedAt":"2026-11-04T09:07:24.956Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/camp","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}